Hot Investor Mandate 3: Venture and Growth Capital Firm Invests in New Life Science Technologies With Clear Path to Approval

7 Sep

A healthcare-focused venture capital and growth equity firm currently manages ~$750 million, providing $15-$30 million of equity capital per company over the life of the investment. The firm is primarily looking for companies throughout North America and Europe.

The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities whereby the company has a clear path through regulatory approval, reimbursement, and commercialization. The firm is generally open in terms of indications.

The firm looks for management teams that are very willing to work alongside them, and most always looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: